Combination therapy as an effective tool for treatment of drug-resistant viral infections

2020 ◽  
pp. 157-182
Author(s):  
Musa Marimani ◽  
Aijaz Ahmad ◽  
Adriano Duse
Keyword(s):  
Combination Therapy ◽  
Viral Infections ◽  
Drug Resistant

scholarly journals Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis

2016 ◽  
Vol 9 (8) ◽  
pp. 1025-1037 ◽  
Author(s):  
T. V. A. Nguyen ◽  
T. B. T. Cao ◽  
O. W. Akkerman ◽  
S. Tiberi ◽  
D. H. Vu ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Multi Drug Resistant Tuberculosis

scholarly journals Combination therapy protects macaques against advanced Marburg virus disease

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Robert W. Cross ◽  
Zachary A. Bornholdt ◽  
Abhishek N. Prasad ◽  
Viktoriya Borisevich ◽  
Krystle N. Agans ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Rhesus Monkeys ◽  
Viral Infections ◽  
Virus Disease ◽  
Marburg Virus ◽  
Therapeutic Window ◽  
Post Inoculation ◽  
Primate Model ◽  
Lethal Infection ◽  
Human Primate

AbstractMonoclonal antibodies (mAbs) and remdesivir, a small-molecule antiviral, are promising monotherapies for many viruses, including members of the genera Marburgvirus and Ebolavirus (family Filoviridae), and more recently, SARS-CoV-2. One of the major challenges of acute viral infections is the treatment of advanced disease. Thus, extending the window of therapeutic intervention is critical. Here, we explore the benefit of combination therapy with a mAb and remdesivir in a non-human primate model of Marburg virus (MARV) disease. While rhesus monkeys are protected against lethal infection when treatment with either a human mAb (MR186-YTE; 100%), or remdesivir (80%), is initiated 5 days post-inoculation (dpi) with MARV, no animals survive when either treatment is initiated alone beginning 6 dpi. However, by combining MR186-YTE with remdesivir beginning 6 dpi, significant protection (80%) is achieved, thereby extending the therapeutic window. These results suggest value in exploring combination therapy in patients presenting with advanced filovirus disease.

Mortality in patients with community-onset pneumonia at low risk of drug-resistant pathogens: Impact of β-lactam plus macrolide combination therapy

Respirology ◽  
2017 ◽  
Vol 23 (5) ◽  
pp. 526-534 ◽  
Author(s):  
Junya Okumura ◽  
Yuichiro Shindo ◽  
Kunihiko Takahashi ◽  
Masahiro Sano ◽  
Yasuteru Sugino ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Low Risk ◽  
Drug Resistant ◽  
Community Onset

scholarly journals Rational combination therapy in resistant arterial hypertension

2011 ◽  
Vol 17 (4) ◽  
pp. 384-390
Author(s):  
I. V. Emelianov ◽  
A. O. Konradi
Keyword(s):  
Combination Therapy ◽  
Arterial Hypertension ◽  
Resistant Hypertension ◽  
Drug Resistant ◽  
Therapeutic Approaches ◽  
Rational Combination ◽  
Resistant Arterial Hypertension

The article reviews therapy in drug-resistant hypertension. Current therapeutic approaches to treatment and rational combination therapy are discussed.

Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection

2000 ◽  
Vol 61 (2) ◽  
pp. 181-186 ◽  
Author(s):  
Catherine Tamalet ◽  
Christophe Pasquier ◽  
Nouara Yahi ◽  
Philippe Colson ◽  
Isabelle Poizot-Martin ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Virological Response ◽  
Drug Resistant ◽  
Resistant Mutants ◽  
Hiv 1

scholarly journals Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia

2019 ◽  
Vol 7 (7) ◽  
pp. 1106-1119 ◽  
Author(s):  
Yorleny Vicioso ◽  
Hermann Gram ◽  
Rose Beck ◽  
Abhishek Asthana ◽  
Keman Zhang ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Combination Therapy ◽  
Lymphoblastic Leukemia ◽  
Drug Resistant

Rifampicin

1970 ◽  
Vol 8 (3) ◽  
pp. 11-12
Keyword(s):  
Messenger Rna ◽  
Viral Infections ◽  
Drug Resistant ◽  
Gram Positive ◽  
Gram Negative ◽  
Low Concentrations ◽  
Resistant Mutants ◽  
Gram Negative Organisms

Rifampicin (Rifadin-Lepetit; Rimactane-Ciba) is a semi-synthetic antibiotic derived from Streptomyces mediterranei which inhibits the synthesis of bacterial messenger-RNA. In vitro it is active against Gram-positive organisms and mycobacteria in low concentrations (0.0002 – 0.5 mcg/ml); and against Gram-negative organisms in higher concentrations (1 – 10 mcg/ml). Drug-resistant mutants readily emerge if rifampicin is used alone.1 It is already established as an important agent in the treatment of tuberculosis. Its usefulness in other bacterial and in viral infections is uncertain.

Sign in / Sign up

Export Citation Format

Share Document